 Personalis is a small-cap cancer genomics company with a next-gen cancer diagnostics platform whose stock has lost over 80 of its value over the past twelve months. Personalis is reporting substantial losses, however, the companys strong balance sheet could provide them with enough runway to prove they are a legitimate player in a 30B market. 